Recent advances in PUVA photochemotherapy and PDT for the treatment of cancer

Current Pharmaceutical Design

Volumn 16, Issue 16, 2010, Pages 1863-1876

  Nagy, Eszter Marta ^a   Via, Lisa Dalla ^a   Ronconi, Luca ^a   Fregona, Dolores ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anticancer activity; PDT; Photochemotherapy; Photosensitizer; Porphyrin; Psoralen; PUVA

Indexed keywords

11 DIMETHYLAMINOPROPOXY 4 METHYLBENZOFURO[3,2 G] COUMARIN; 3,4 BENZO 8 (3 DIMETHYLAMINOPROPOXY) 4' METHYLFURO [3,2 G]COUMARIN; ALLOPSORALEN; AMINOLEVULINIC ACID; ANGELICIN; ANTINEOPLASTIC AGENT; BENZOALLOPSORALEN; BERGAPTEN; CARBOPLATIN; CISPLATIN; CPG 55847; GADOLINIUM TEXAPHYRIN; HEMATOPORPHYRIN; INTERFERON; LUTETIUM TEXAPHYRIN; METHOXSALEN; PALLADIUM BACTERIOPHEOPHORBIDE; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; PHTHALOCYANINE ZINC; PORPHYCENE DERIVATIVE; PORPHYRIN DERIVATIVE; PROTOPORPHYRIN; PSORALEN; PSORALEN DERIVATIVE; PYRIDAZINO[4,3 H]PSORALEN; RETINOID; TEMOPORFIN; TRIOXYSALEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTEPORFIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; BLADDER CANCER; BONE MARROW SUPPRESSION; BRAIN CANCER; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DIGESTIVE SYSTEM CANCER; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ELECTRON THERAPY; ERYTHEMA; EYE DISEASE; GASTROINTESTINAL SYMPTOM; GENOTOXICITY; HEAD AND NECK TUMOR; HUMAN; KAPOSI SARCOMA; LIGHT; LUNG CANCER; MELANOMA; NAUSEA; NONHUMAN; PANCREAS CANCER; PHOTOCHEMOTHERAPY; PHOTODYNAMIC THERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; PUVA; RETINA MACULA AGE RELATED DEGENERATION; SKIN CANCER; SKIN DISEASE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; VITILIGO; VOMITING;

ANIMALS; COORDINATION COMPLEXES; DRUG DESIGN; HEMATOPORPHYRINS; HUMANS; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PSORALENS; PUVA THERAPY;

EID: 77953513143     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791209018     Document Type: Article

References (146)

1. Ackroyd R, Kelty C, Brown N, Reed M. The history ofphotodetection and photodynamic therapy. J Photochem Photobiol 2001; 74: 656-69.
2. Finsen NF. In: Phototherapy. London, Edward Arnold 1901; 1-36.
3. von Tappeiner H, Jesionek A. Therapeutische Versuche mitfluoreszierenden Stoffen. Munch Med Wochenschr 1903; 7: 2042-4.
4. Morison WL. Phototherapy and Photochemotherapy: An update. Semin Cutan Med Surg 1999; 18: 297-306.
5. Krutmann J, Morita A. Mechanisms of Ultraviolet (UV) B and UVA phototherapy. J Invest Dermatol Symp Proc 1999; 4: 70-2.
6. Sarici SÜ, Alpay F, Ünay B, Özcan O, Gökçay E. Comparison ofthe efficacy of conventional special blue light phototherapy and fiberoptic phototherapy in the management of neonatalhyperbilirubinaemia. Acta Paediatr 1999; 88: 1249-53.
7. Tuck A, Smith S, Whitesides JF, Larcom L. Hypersensitivity oflymphocytes from chronic lymphocytic leukemia patients to Ultraviolet light-C radiation. Leuk Lymp 1999; 36: 169-77.
8. Girotti AW. New trends in photobiology: Photosensitized oxidationof cholesterol in biological systems: Reaction pathways, cytotoxiceffects and defense mechanisms. J Photochem Photobiol B: Biol 1992; 13: 105-18.
9. Nonell S, Redmond RW. On the determination of quantum yieldsfor singlet molecular oxygen photosensitization. J Photochem Photobiol B: Biol 1994; 22: 171-2.
10. Pope AJ, Bown SG. Photodynamic. Br J Urol 1991; 68: 1-9.
11. Stepp H. Principles of clinical photodynamic therapy. Acta Endosc 2003; 33: 1-22.
12. Spikes J. In: Smith KC Ed, The science of photobiology. NewYork: Plenum Press 1989; pp. 87-112.
13. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3: 380-7.
14. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90: 889-905.
15. Ochsner M. Photophysical and photobiological processes in thephotodynamic therapy of tumours. J Photochem Photobiol B: Biol 1997; 39: 1-18.
16. Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ. Photodynamictherapy: a new concept in medical treatment. Braz J Med Biol Res 2000; 33: 869-80.
17. Morison WL. Psoralen ultraviolet A therapy in 2004. Photodermatol Photoimmunol Photomed 2004; 20: 315-20.
18. Knobler R, Barr ML, Couriel DR, Ferrara JML, French LE, Jaksch P, et al. Extracorporeal photopheresis: Past, present, and future. J Am Acad Dermatol 2009; 61: 652-65.
19. Dalla Via L, Magno SM. Photochemotherapy in the treatment of cancer. Curr Med Chem 2001; 8: 1405-18.
20. Szacilowski K, Macyk W, Drzewiecka-Matuszek A, Brindell M, Stochel G. Bioinorganic photochemistry: frontiers and mechanisms. Chem Rev 2005; 105: 2647-94.
21. Gardner CM, Jacques SL, Welch AJ. Fluorescence spectroscopy of tissue: recovery of intrinsic fluorescence from measured fluorescence. Appl Opt 1996; 35: 1780-92.
22. Richards-Kortum R, Sevick-Muraca E. Quantitative opticalspectroscopy for tissue diagnosis. Annu Rev Phys Chem 1996; 47:555-606.
23. Bonnett R. In: McCleverty JA, Meyer TJ, Eds. Metal complexesfor photodynamic therapy. Comprehensive Coordination Chemistry II; From biology to nanotechnology. Oxford: Elsevier Pergamon 2004; vol. 9: pp. 945-1003.
24. Dougherty TJ, Marcus SL. Photodynamic therapy. Eur J Cancer 1992; 28: 1734-42.
25. Brancaleon L, Moseley H. Laser and non-laser light sources forphotodynamic therapy. Lasers Med Sci 2002; 17: 173-86.
26. Diffey BL, Farr PM. An appraisal of ultraviolet lamps used for thephototherapy of psoriasis. Br J Dermatol 1987; 117: 49-56.
27. Schneider LA, Hinrichs R, Scharffetter-Kochanek K. Phototherapy and photochemotherapy. Clin Dermatol 2008; 26: 464-76.
28. Barolet D. Light-Emitting Diodes (LEDs) in dermatology. Semin Cutan Med Surg 2008; 27: 227-38.
29. Santana L, Uriarte E, Roleira F, Milhazes N, Borges F. Furocou-marins in medicinal chemistry. Synthesis, natural occurrence and biological activity. Curr Med Chem 2004; 11: 3239-61.
30. Bethea D, Fullmer B, Syed S, Seltzer G, Tiano J, Rischko C, et al. Psoralen photobiology and photochemotherapy: 50 years of science and medicine. J Dermatol Sci 1999; 19: 78-88.
31. Caffieri S. Furocoumarin photolysis: chemical and biologicalaspects. Photochem Photobiol Sci 2002; 1: 149-57.
32. Kitamura N, Kohtani S, Nakagaki R. Molecular aspects offurocoumarin reactions: photophysics, photochemistry, photobio-logy, and structural analysis. J Photochem Photobiol C: Photo chem Rev 2005; 6: 168-85.
33. Pathak MA, Fitzpatrick TB. The evolution of photochemotherapywith psoralens and UVA (PUVA): 2000 BC to 1992 AD. J Photo chem Photobiol B: Biol 1992; 14: 3-22.
34. Diffey B. The contribution of medical physics to the developmentof psoralen photochemotherapy (PUVA) in the UK: a personalreminiscence. Phys Med Biol 2006; 51: R229-44.
35. Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photo-chemotherapy of psoriasis with oral methoxsalen and longwaveultraviolet light. N Engl J Med 1974; 291: 1207-11.
36. Roelandts R. The history of photochemotherapy. Photodermatol Photoimmunol Photomed 1991; 8: 184-9.
37. Wolff K, Gschnait F, Hönigsmann H, Konrad K, Parrish JA, Fitzpatrick TB. Phototesting and dosimetry for photochemotherapy. Br J Dermatol 1977; 96: 1-10.
38. Taylor DK, Anstey AV, Coleman AJ, Diffey BL, Farr PM, Ferguson J, et al. Guidelines for dosimetry and calibration inultraviolet radiation therapy. Br J Dermatol 2002; 146: 755-63.
39. El Mofty AM. Preliminary clinical report on treatment of Leucoderma with Ammi Majus Linn. J Roy Egypt Med Assoc 1948; 31: 651-65.
40. Wolff K, Hönigsmann H, Gschnait F, Konrad K. Photochemotherapie bei Psoriasis. Klinische Erfahrungen bei 152 Patienten. Dtsch Med Wochenschr 1975; 100: 2471-7.
41. Norris PG, Hawk JLM, Baker C, Bilsland D, Diffey BL, Farr PM, et al. British Photodermatology Group guidelines for PUVA. Br JDermatol 1994; 130: 246-55.
42. Di Renzo M, Sbano P, De Aloe G, Pasqui AL, Rubegni P, Ghezzi A, et al. Extracorporeal photopheresis affects co-stimulatorymolecule expression and interleukin-10 production by dendriticcells in graft-versus-host disease patients. Clin Exp Immunol 2008;151: 407-13.
43. Wackernagel A, Hofer A, Legat F, Kerl H, Wolf P. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapyin patients with mycosis fungoides. Br J Dermatol 2006; 154: 519-23.
44. Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007; 157: 433-40.
45. Miller JD, Kirkland EB, Santo Domingo D, Scull H, Jekutis B, Dallas M, et al. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 2007; 23: 163-71.
46. Knobler RM, Edelson RL. Cutaneous T cell lymphoma. Med Clin North Am 1986; 70: 109-38.
47. Pichardo DA, Querfeld C, Guitart J, Kuzel TM, Rosen ST. Cutaneous T-cell lymphoma: a paradigm for biological therapies. Leuk Lymp 2004; 45: 1755-65.
48. Knobler E. Current management strategies for cutaneous T-celllymphoma. Clin Dermatol 2004; 22: 197-208.
49. Kuzel T, Roenigk HH, Samuelson E, Herrmann JJ, Hurria A, Rademaker AW, et al. Effectiveness of interferon alfa-2a combinedwith phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 1995; 13: 257-63.
50. Stadler R, Otte HG, Luger T, Henz BM, Kühl P, Zwingers T, et al. Prospective randomized multicenter clinical trial on the use ofinterferon -2a plus acitretin versus interferon -2a Plus PUVA inpatients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-81.
51. Rupoli S, Barulli S, Guiducci B, Offidani M, Mozzicafreddo G, Simonacci M, et al. Low dose interferon-alpha2b combined withPUVA is an effective treatment of early stage mycosis fungoides:results of a multicenter study. Haematologica 1999; 84: 809-13.
52. Anadolu RY, Birol A, Sanli H, Erdem C, Türsen Ü. Mycosisfungoides and Sezary syndrome: therapeutic approach and outcomein 113 patients. Int J Dermatol 2005; 44: 559-65.
53. Thomsen K, Hammar H, Molin L, Volden G. Retinoids plus PUVA(rePUVA) and PUVA in mycosis fungoides, plaque stage. Acta Derm Venereol 1989; 69: 536-8.
54. Michaelis S, Cozzio A, Kempf W, Graf P, Burg G, Dummer R. Combination of bexarotene and psoralen-UVA therapy in a patientwith mycosis fungoides. Dermatology 2004; 209: 72-4.
55. Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatmentusing bexarotene and PUVA: A case series. J Am Acad Dermatol 2004; 51: 570-3.
56. Quirós PA, Jones GW, Kacinski BM, Braverman IM, Heald PW, Edelson RL, et al. Total skin electron beam therapy followed byadjuvant psoralen/ultraviolet-A light in the management of patientswith T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Rad Oncol Biol Phys 1997; 38: 1027-35.
57. Duvic M, Chiao N, Talpur R. Extracorporeal photopheresis for thetreatment of cutaneous T-cell lymphoma. J Cutan Med Surg 2003;7(S4): 3-7.
58. Viola G, Vedaldi D, Dall'Acqua F, Fortunato E, Basso G, Bianchi N, et al. Induction of -globin mRNA, erythroid differentiation and apoptosis in UVA-irradiated human erythroid cells in the presenceof furocumarin derivatives. Biochem Pharmacol 2008; 75: 810-25.
59. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, et al. Treatment of cutaneous T-cell lymphoma by extracor-poreal photochemotherapy. Preliminary results. N Engl J Med 1987; 316: 297-303.
60. Zic JA, Stricklin GP, Greer JP, Kinney MC, Shyr Y, Wilson DC, et al. Long-term follow-up of patients with cutaneous T-celllymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996; 35: 935-45.
61. Knobler RM, Pirker R, Kokoschka EM, Ludwig H, Linkesch W, Micksche M. Experimental treatment of chronic lymphocyticleukemia with extracorporeal photochemotherapy. Initialobservations. Blut 1990; 60: 215-8.
62. Dall'Acqua F, Viola G, Vedaldi D. In: Hoorspool WM, Lenci F, Eds. Handbook of Organic Photochemistry and Photobiology. USA, Boca Raton: CRC Press 2004; pp. 1-17.
63. Wolf P, Nghiem DX, Walterscheid JP, Byrne S, Matsumura Y, Matsumura Y, et al. Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis. Am J Pathol 2006; 169: 795-805.
64. Zarebska Z, Zielinska J, Zhukov I, Wlodzimierz M. A poptosisinduced by membrane damage in human lymphocytes; effects ofarachidonic acid and its photoproducts. Acta Biochim Pol 2005; 52:179-94.
65. Joshi PC, Pathak MA. Production of singlet oxygen and superoxideradicals by psoralens and their biological significance. BiochemBiophys Res Commun 1983; 112: 638-45.
66. Midden WR. In: Gasparro FP, Ed. Chemical mechanisms of the bioeffects of furocoumarins: the role of the reactions with proteins,lipids, and other cellular components, in Psoralen DNA. Photobiology. USA, Boca Raton: CRC Press 1988; pp. 1-49.
67. Baron ED, Stevens SR. Phototherapy for cutaneous T-celllymphoma. Dermatol Therapy 2003; 16: 303-10.
68. Mimouni D, David M, Feinmesser M, Coire CI, Hodak E. Vitiligo-like leucoderma during photochemotherapy for mycosis fungoides.Br J Dermatol 2001; 145: 1008-14.
69. Todes-Taylor N, Abel EA, Cox AJ. The occurrence of vitiligo afterpsoralens and ultraviolet A therapy. J Am Acad Dermatol 1983; 9:526-32.
70. Stern RS, Nichols KT, Väkevä LH. Malignant melanoma inpatients treated for psoriasis with methoxsalen (Psoralen) and Ultraviolet A radiation (PUVA). N Engl J Med 1997; 336: 1041-5.
71. Smith MA, Freidlin B, Ries LA, Simon R. Trends in reportedincidence of primary malignant brain tumors in children in theUnited States. J Natl Cancer Inst 1998; 90: 1269-84.
72. Raquet N, Schrenk D. Relative photomutagenicity of furocou-marins and limettin in the hypoxanthine phosphoribosyl transferaseassay in V79 cells. Chem Res Toxicol 2009; 22: 1639-47.
73. Kirkland DJ, Creed KL, Mannisto P. Comparative bacterial muta-genicity studies with 8-methoxypsoralen and 4,5,8-trimethyl-psoralen in the presence of near-ultraviolet light and in the dark. Mutat Res Gen Toxicol 1983; 116: 73-82.
74. Venturini S, Tamaro M, Monti-Bragadin C, Carlassare F. Mutagenicity in Salmonella typhimurium of some angelicin deri-vatives proposed as new monofunctional agents for the photo-chemotherapy of psoriasis. Mutat Res Gen Toxicol 1981; 88: 17-22.
75. Hook GJ, Heddle JA, Marshall RR. On the types of chromosomalaberrations induced by 8-methoxypsoralen. Cytogenet Cell Genet 1983; 35: 100-3.
76. Bisagni E. Synthesis of psoralens and analogues, J Photo chem Photobiol B: Biol 1992; 14: 23-46.
77. Rodighiero G, Dall'Acqua F, Averbeck D. In: Gasparro FP, Ed. Psoralen DNA photobiology. Florida, Boca Raton: CRC Press 1988; pp. 37-114.
78. Bordin F, Dall'Acqua F, Guiotto A. Angelicins, angular analoguesof psoralens: Chemistry, photochemical, photobiological and phototherapeutic properties. Pharmacol Ther 1991; 52: 331-63.
79. Caffieri S, Rodighiero P, Vedaldi D, Dall'Acqua F. Methylallo-psoralen-thymine 3,4- and 4',5'-monoadducts formed in thephotoreaction with DNA. Photochem Photobiol 1985; 42: 361-6.
80. Vedaldi D, Dall'Acqua F, Guiotto A, Caffieri S, Baccichetti F, Knox CN, et al. Photochemical, photophysical and photobiologicalproperties of some methylallopsoralens which are potential agentsfor photochemotherapy. Biochim Biophys Acta 1987; 925: 101-8.
81. Gia O, Mobilio S, Palumbo M, Pathak MA. Benzo- and tetrahy-drobenzo-psoralen congeners: DNA binding and photobiologicalproperties. Photochem Photobiol 1993; 57: 497-503.
82. Dalla Via L, Gia O, Magno SM, Santana L, Teijeira M, Uriarte E. New tetracyclic analogues of photochemotherapeutic drugs 5-MOPand 8-MOP: synthesis, DNA interaction, and antiproliferativeactivity. J Med Chem 1999; 42: 4405-13.
83. Dalla Via L, Uriarte E, Quezada E, Dolmella A, Ferlin MG, Gia O. Novel pyrone side tetracyclic psoralen derivatives: synthesis and photobiological evaluation. J Med Chem 2003; 46: 3800-10.
84. Dalla Via L, Uriarte E, Santana L, Magno SM, Gia O. Methylderivatives of tetracyclic psoralen analogues: antiproliferativeactivity and interaction with DNA. Arkivoc 2004; V: 131-46.
85. Dalla Via L, Mammi S, Uriarte E, Santana L, Lampronti I, Gambari R, et al. New furan side tetracyclic allopsoralenderivatives: synthesis and photobiological evaluation. J Med Chem 2006; 49: 4317-26.
86. Dalla Via L, González-Gómez JC, Pérez-Montoto LG, Santana L, Uriarte E, Magno S, et al. A new psoralen derivative with enlarged antiproliferative properties. Bioorg Med Chem Lett 2009; 19:2874-6.
87. von Tappeiner H, Jodlbauer A. Ueber die Wirkung derphotodynamischen (fluorescierenden) Stoffe auf Protozoan undEnzyme. Dtsch Arch Klin Med 1904; 80: 427-87.
88. Raab O. Über die Wirkung fluoreszierender Stoffe auf Infusorien. Z Biol 1900; 39: 524-6.
89. Figge FHJ, Wieland GS, Manganiello LOJ. Cancer detection and therapy. Affinity of neoplastic, embryonic and traumatized tissuesfor porphyrins and metalloporphyrins. Proc Soc Exp Biol Med 1948; 68: 640-1.
90. Lipson R, Baldes E, Olson A. The use of a derivative ofhematoporphyrin in tumor detection. J Nat Cancer Inst 1961; 26: 1-11.
91. Juarranz A, Jaén P, Sanz-Rodríguez F, Cuevas J, González S. Photodynamic therapy of cancer. Basic principles and applications.Clin Transl Oncol 2008; 10: 148-54.
92. Dougherty TJ, Grindey GB, Fiel R, Weishaupt KR, Boyle DG. Photoradiation therapy II. Cure of animal tumors withhematoporphyrin and light. J Natl Cancer Inst 1975; 55: 115-21.
93. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignanttumors. Cancer Res 1978; 38: 2628-35.
94. Triesscheijn M, Baas P, Schellens JHM, Stewart FH. Photody-namic therapy in oncology. Oncologist 2006; 11: 1034-44.
95. Zuluaga MF, Lange N. Combination of Photodynamic Therapywith Anti-Cancer Agents. Curr Med Chem 2008; 15: 1655-73.
96. Pervaiz S, Olivo M. Art and science of photodynamic therapy. ClinExp Pharmacol Physiol 2006; 33: 551-6.
97. Mang TS. Lasers and light sources for PDT: Past, present andfuture. Photodiag Photodyn Ther 2004; 1: 43-8.
98. van den Bergh H. On the evolution of some endoscopic lightdelivery systems for photodynamic therapy. Endoscopy 1998; 30:392-407.
99. Tandon YK, Yang MF, Baron ED. Role of photodynamic therapyin psoriasis: a brief review. Photodermatol PhotoimmunolPhotomed 2008; 24: 222-30.
100. Pushpan SK, Venkatraman S, Anand VG, Sankar J, Parmeswaran D, Ganesan S, et al. Porphyrins in photodynamic therapy - a searchfor ideal photosensitizers. Curr Med Chem Anti-Cancer Agents 2002; 2: 187-207.
101. Hatz S, Lambert JD, Ogilby PR. Measuring the lifetime of singletoxygen in a single cell: addressing the issue of cell viability. Photochem Photobiol Sci 2007; 6: 1106-16.
102. Robertson CA, Hawkins Evans D, Abrahamse H. Photodynamictherapy (PDT): A short review on cellular mechanisms and cancerresearch applications for PDT. J Photochem Photobiol B: Biol 2009; 96: 1-8.
103. Ketabchi A, MacRobert A, Speight PM, Bennett JH. Induction ofapoptotic cell death by photodynamic therapy in humankerationcytes. Arch Oral Biol 1998; 43: 143-9.
104. Kessel D, Vicente MGH, Reiners JJ. Initiation of apoptosis and autophagy by photodynamic therapy. Laser Med Surg 2006; 38:482-8.
105. O'Connor AE, Gallagher WM, Byrne AT. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinicaladvances in photodynamic therapy. Photochem Photobiol 2009; 85:1053-74.
106. Josefsen LB, Boyle RW. Photodynamic therapy and thedevelopment of metal-based photosensitisers. Metal-Based Drugs 2008; 2008: 276109.
107. Dougherty TJ, Mang TS. Characterization of intra-tumoralporphyrin following injection of hematoporphyrin derivative or itspurified component. Photochem Photobiol 1987; 46: 67-70.
108. el-Sharabasy MM, El-Waseef AM, Hafez MM, Salim SA. Porphyrin metabolism in some malignant diseases. Br J Cancer 1992; 65: 409-12.
109. Richter AM, Kelly B, Chow J, Liu DJ, Towers GHN, Dolphin D, et al. Preliminary studies on a more effective phototoxic agent thanhematoporphyrin. J Natl Cancer Inst 1987; 79: 1327-32.
110. Levy JG, Jones CA, Pilson LA. The preclinical and clinical development and potential application of benzoporphyrin derivative. Int Photodyn 1994; 1: 3-5.
111. Stockert JC, Cañete M, Juarranz A, Villanueva A, Horobin RW, Borrell JI, et al. Porphycenes: facts and prospects in photodynamictherapy of cancer. Curr Med Chem 2007; 14: 997-1026.
112. Gottfried V, Davidi R, Averguj C, Kimel SJ. In vivo damage tochorioallantoic membrane blood vessels by porphycene-inducedphotodynamic therapy. Photochem Photobiol B: Biol 1995; 30:115-21.
113. Toledano H, Edrei R, Kimel SJ. Photodynamic damage byliposome-bound porphycenes: comparison between in vitro and invivo models. Photochem Photobiol B: Biol 1998; 42: 20-7.
114. Wohrle D, Hirth A, Bogdahn-Rai T, Schnurpfeil G, Shopova M. Photodynamic therapy of cancer: Second and third generations ofphotosensitizers. Russ Chem Bull 1998; 47: 836-45.
115. Farrer NJ, Salassa L, Sadler PJ. Photoactivated chemotherapy(PACT): the potential of excited-state d-block metals in medicine. Dalton Trans 2009; 10690-701.
116. Chen Q, Huang Z, Luck D, Beckers J, Brun PH, Wilson BC, et al. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamictherapy of prostate cancers. Photochem Photobiol 2002; 76: 438-45.
117. Trachtenberg J, Bogaards A, Weersink RA, Haider MA, Evans A, McCluskey SA et al. Vascular targeted photodynamic therapy withpalladium-bacteriopheophorbide photosensitizer for recurrentprostate cancer following definitive radiation therapy: Assessmentof safety and treatment response. J Urol 2007; 178: 1974-9.
118. Mang TS, Allison R, Hewson G, Snider W, Moskowitz R. A phase II / III clinical study of tin ethyl etiopurpurin(Purlytin)-inducedphotodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J Sci Am 1998, 4: 378-84.
119. Mody TD, Sessler JL. Texaphyrins: A new approach to drugdevelopment. J Porphyrins Phthalocyanines 2001; 5: 134-42.
120. ®. J Photochem PhotobiolB Biol 1996; 32: 3-9.
121. Zharkova NN, Kozlov DN, Smirnov VV. In: Brault D, Jori G, Moan J, Ehrenberg B, Eds. Photodynamic therapy of cancer II.France, Proceeding of the International Society for Optical Engineering 1995; vol. 2325: pp. 400-3.
122. Che CM, Sun RWY, Yu WY, Ko CB, Zhu N, Sun H. Gold(III)porphyrins as a new class of anticancer drugs: cytotoxicity, DNAbinding and induction of apoptosis in human cervix epitheloidcancer cells. Chem Commun 2003; 1718-9.
123. Lum CT, Yang ZF, Li HY, Sun RWY, Fan ST, Poon RTP, et al. Gold(III) compound is a novel chemocytotoxic agent forhepatocellular carcinoma. Int J Cancer 2006; 118: 1527-38.
124. Haeubl M, Reith ML, Gruber B, Karner U, Müller N, Knör G, et al. DNA interactions and photocatalytic strand cleavage by artificialnucleases based on water-soluble gold(III) porphyrins. J Biol InorgChem 2009; 14: 1037-52.
125. Farrer NJ, Sadler PJ. Photochemotherapy: targeted activation of metal anticancer complexes. Aust J Chem 2008; 61: 669-74.
126. DeRosa MC, Crutchley RJ. Photosensitized singlet oxygen and itsapplications. Coord Chem Rev 2002; 233-234: 351-71.
127. Kratochwil NA, Parkinson JA, Bednarski PJ, Sadler PJ. Nucleotideplatination induced by visible light. Angew Chem Int Ed 1999; 38:1460-3.
128. Krazt F, Müller IA, Ryppa C, Warnecke A. Prodrug strategies inanticancer chemotherapy. Chem Med Chem 2008; 3: 20-53.
129. Clarke MJ. Ruthenium metallo pharmaceuticals. Coord Chem Rev 2003; 236: 209-33.
130. Moucheron C, Kirsch-De Mesmaeker A, Kelly JM. Photoreactionsof ruthenium (II) and osmium (II) complexes with deoxyribo-nucleic acid (DNA). J Photochem Photobiol B: Biol 1997; 40: 91-106.
131. Elias B, Kirsch-De Mesmaeker A. Photo-reduction ofpolyazaaromatic Ru(II) complexes by biomolecules and possibleapplications. Coord Chem Rev 2006; 250: 1627-41.
132. Cordier C, Pierre VC, Barton JK. Insertion of a bulky rhodiumcomplex into a DNA cytosine cytosine mismatch: an NMRsolution study. J Am Chem Soc 2007; 129: 12287-95.
133. Kelland L. The resurgence of platinum-based cancer chemo-therapy. Nat Rev Cancer 2007; 7: 573-84.
134. Hall MD, Hambley TW. Platinum(IV) antitumour compounds:their bioinorganic chemistry. Coord Chem Rev 2002; 232: 49-67.
135. Hall MD, Mellor HR, Callaghan R, Hambley TW. Basis for design and development of platinum(IV) anticancer complexes. J MedChem 2007; 50: 3403-11.
136. Bednarski PJ, Mackay FS, Sadler PJ. Photoactivatable platinumcomplexes. Anti-Cancer Agents Med Chem 2007; 7: 75-93.
137. Müller P, Schröder B, Parkinson J, Kratochwil NA, Coxall RA, Parkin A, et al. Nucleotide cross-linking induced by photoreactionsof platinum(IV)-azide complexes. Angew Chem Int Ed 2003, 42:335-9.
138. Ronconi L, Sadler PJ. Unprecedented carbon-carbon bondformation induced by photoactivation of a platinum(IV)-diazidocomplex. Chem Commun 2008; 235-7.
139. 2] with 1-methylimidazole. Chem Eur J 2009; 15: 1588-96.
140. Mackay FS, Moggach SA, Collins A, Parsons S, Sadler PJ. Photoactive trans ammine/amine diazido platinum(IV) complexes. Inorg Chim Acta 2009; 362: 811-9.
141. Kašpárková J, Mackay FS, Brabec V, Sadler PJ. Formation ofplatinated GG cross-links on DNA by photoactivation of aplatinum(IV) azide complex. J Biol Inorg Chem 2003; 8: 741-5.
142. Mackay FS, Woods JA, Heringová P, Kašpárková J, Pizarro AM, Moggach SA, et al. A potent cytotoxic photoactivated platinumcomplex. Proc Natl Acad Sci USA 2007; 104: 20743-8.
143. Bednarski PJ, Grünert R, Zielzki M, Wellner A, Mackay FS, Sadler PJ. Light-activated destruction of cancer cell nuclei by platinumdiazide complexes. Chem Biol 2006; 13: 61-7.
144. Berland KM. Two-photon excitation fluorescence microscopy. Annu Rev Biomed Eng 2000; 2: 399-429.
145. ®. Photo chem Photobiol 2007; 83: 1441-8.
146. Ford PC. Polychromophoric metal complexes for generating thebioregulatory agent nitric oxide by single- and two-photonexcitation. Acc Chem Res 2008; 41: 190-200.